Literature DB >> 10397808

Dose-dependent reduction of apoptosis in nutrient-limited cultures of NS/0 myeloma cells transfected with the E1B-19K adenoviral gene.

S Mercille1, P Jolicoeur, C Gervais, D Paquette, D D Mosser, B Massie.   

Abstract

It is now well documented that apoptosis represents the prevalent mode of death in lymphoid cultures and occurs spontaneously in late-exponential phase of batch cultures following nutrient exhaustion. In an attempt to enhance the cell survival of these cell lines, we have initially engineered nonproducing NS/0 myeloma cells with a vector expressing the adenoviral E1B-19K protein. NS/0 cells transfected with E1B-19K were found to be more resistant to apoptosis occurring in the late phase of batch culture and under stressful conditions such as cultivation in glutamine-free medium or following heat shock. In this study, we have characterised a number of NS/0 subclones constitutively expressing different levels of E1B-19K, as well as several subclones in which the expression of E1B-19K was regulated by a tetracycline-controllable gene switch. We have found that a threshold E1B-19K level was required in order to achieve protection against apoptosis. The extent of resistance against cell death induced by nutrient deprivation in glutamine-free medium and in the late phase of batch cultures correlated with the level of E1B-19K expression up to an optimal level where further increases in E1B-19K levels did not result in significant additional protection. To assess the effects of E1B-19K on antibody productivity, an apoptosis-resistant NS/0 clone was then transfected with a chimeric antibody construct. Despite their improved viability, the antibody productivity of E1B-19K clones in batch culture was not significantly improved. Moreover, while the use of E1B-19K considerably delayed cell death, cells eventually died by apoptosis. Surprisingly, E1B-19K had no beneficial effect on the efficiency of fusion of NS/0 myelomas and splenocytes for the generation of hybridoma cells. Furthermore, the resulting hybridomas, although expressing E1B-19K at levels comparable to the myeloma parent, were no longer resistant to apoptosis. This indicates that the ability of E1B-19K to prevent apoptosis is not only dose-dependent but also seems to be cell-type dependent. Copyright 1999 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397808     DOI: 10.1002/(sici)1097-0290(19990605)63:5<516::aid-bit2>3.0.co;2-9

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

1.  Analysis of Chinese hamster ovary cell metabolism through a combined computational and experimental approach.

Authors:  Ning Chen; Mark H Bennett; Cleo Kontoravdi
Journal:  Cytotechnology       Date:  2013-11-29       Impact factor: 2.058

2.  Regulating apoptosis in mammalian cell cultures.

Authors:  Nilou Arden; M J Betenbaugh
Journal:  Cytotechnology       Date:  2006-07-01       Impact factor: 2.058

3.  Apoptosis-resistant NS/0 E1B-19K myelomas exhibit increased viability and chimeric antibody productivity under cell cycle modulating conditions.

Authors:  S Mercille; B Massie
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

4.  Protection of hybridoma cells against apoptosis by a loop domain-deficient Bcl-xL protein.

Authors:  J Charbonneau; E Gauthier
Journal:  Cytotechnology       Date:  2001-09       Impact factor: 2.058

5.  Prolongation of murine hybridoma cell survival in stationary batch culture by Bcl-xL expression.

Authors:  J R Charbonneau; E R Gauthier
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

6.  The cumate gene-switch: a system for regulated expression in mammalian cells.

Authors:  Alaka Mullick; Yan Xu; René Warren; Maria Koutroumanis; Claire Guilbault; Sophie Broussau; Félix Malenfant; Lucie Bourget; Linda Lamoureux; Rita Lo; Antoine W Caron; Amelie Pilotte; Bernard Massie
Journal:  BMC Biotechnol       Date:  2006-11-03       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.